# GLP-1 receptor agonists: Industries

Source page: https://www.materialinsights.org/technologies/glp1_agonists/tech-industries/

#### Industries

The industries and kinds of firm that use or make it, how far they have taken it up and what it does to them
 Made by

- [Innovator pharma and biotech companies](https://www.materialinsights.org/industries/pharmaceuticals/) fast-growing product class Novo Nordisk's 2025 sales included DKK 127 billion of Ozempic and DKK 79 billion of Wegovy ^[5].
- [API manufacturers and CDMOs](https://www.materialinsights.org/industries/pharmaceuticals/) Peptide manufacture Makers of active ingredients produce the peptides for the brand owners and, as patents end, for generic makers.
 Used by

- [Primary care clinics and doctors' practices](https://www.materialinsights.org/industries/healthcare/) Diabetes and obesity care Doctors prescribe them for type 2 diabetes and obesity; more than half of people with diabetes took no diabetes medicine in 2022 ^[4].
- [Health insurers, TPAs and public health schemes](https://www.materialinsights.org/industries/healthcare/) High drug spending Health insurers and public schemes pay for long-term use, and WHO urges pooled buying and tiered prices ^[3].
- [Retail and online pharmacies](https://www.materialinsights.org/industries/healthcare/) Dispensing Pharmacies dispense the pens, which must be kept cool.

as of 2026-11-11

#### Sources

1. [WHO issues global guideline on the use of GLP-1 medicines in treating obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) World Health Organization, 2025
2. [Diabetes (fact sheet)](https://www.who.int/News-Room/Fact-Sheets/Detail/Diabetes) World Health Organization, 2026
3. [Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K)](https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026

## Other sections

- [Summary](https://www.materialinsights.org/technologies/glp1_agonists/index.md)
- [Overview](https://www.materialinsights.org/technologies/glp1_agonists/tech-overview/index.md)
- [Science](https://www.materialinsights.org/technologies/glp1_agonists/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/glp1_agonists/tech-evolution/index.md)
- [Materials](https://www.materialinsights.org/technologies/glp1_agonists/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/glp1_agonists/tech-energy-footprint/index.md)
